Home > > Tom Schirris

Tom Schirris

 Tom Schirris, CSBB PhD since October 2010

WP3: Model validation, refinement and application.

AL3: Evaluation of off-target mitochondrial bioenergetic effects of pharmaceuticals.

This action line aims to develop a model of the skeletal myoblasts and myotubes being able to give a sensitive prediction of mitochondrial toxicity. Effects of pharmaceuticals will be investigated on both human and mice myoblasts and myotubes using a wide range of methods present within the CSBB. This knowledge about off-target bioenergetic effects of pharmaceuticals will be used to validate the model developed in WP 1 and 2. These models will allow for a better understanding and prediction of off-target mitochondrial drug effects and the identification of sensitive biomarkers of drug-induced metabolic changes in muscle. This will contribute to better recognition of adverse bioenergetic effects in the process of drug development and to improve the safety of drug treatment by indentifying patients at risk. 

Contact details:
Centre for Systems Biology & Bioenergetics
Radboud University Nijmegen Medical Centre
Geert Grooteplein 28
Huispost 149
6500 HB Nijmegen
The Netherlands
T: +31-24-3610575
Email: T.Schirris@pharmtox.umcn.nl


Personal Profile:
Tom obtained his Masters degree in Biomedical Sciences in 2010 at the Radboud University Nijmegen, with majors in Toxicology and Pathobiology. He performed his internships at the University of California Irvine and at MSD, where he studied Alzheimers Disease and high throughput toxicity screening respectively. His research interests mainly focus on molecular toxicity.